Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial
| Autor: | Geetha Joseph, Howard A. Burris, Lisa H. Morrissey, F. Anthony Greco, David R. Spigel, Ellen Spremulli, Steven W. Corso, John D. Hainsworth, Joan B. Erland, D. S. Thompson |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Lung Neoplasms Paclitaxel medicine.medical_treatment law.invention Carboplatin chemistry.chemical_compound Organophosphorus Compounds Randomized controlled trial law Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Carcinoma Small Cell Etoposide Aged Chemotherapy business.industry Middle Aged medicine.disease Regimen chemistry Topotecan Female business medicine.drug |
| Zdroj: | The oncologist. 10(9) |
| ISSN: | 1083-7159 |
| Popis: | Purpose. To compare the combination of paclitaxel (Taxol®; Bristol-Myers Squibb, Princeton, NJ, http://www.bms.com) and topotecan (Hycamtin®; Glaxo SmithKline, Philadelphia, http://www.gsk.com) with paclitaxel, carboplatin (Paraplatin®; Bristol-Myers Squibb), and etoposide (Etopophos®, VePesid®; Bristol-Myers Squibb) in patients with previously untreated extensive-stage small cell lung cancer. Patients and Methods. In this phase II trial, 120 patients were randomly allocated to receive either topotecan (1.5 mg/m2 i.v. days 1, 2, and 3) and paclitaxel (175 mg/m2 i.v. day 1) every 21 days orpaclitaxe l (200mg/m2 i.v. day 1), carboplatin (area under the concentration–time curve 6 i.v. day 1), and etoposide (50 mg/100 mg alternating daily by mouth days 1–10) every 21 days, each regimen for a maximum of eight cycles. The primary end points were objective response rate and time to progression. Results. The paclitaxel–carboplatin–etoposide combination produced a significantly higher overall response rate (78% versus 48%), longer median time to progression (7.6 months versus 5.5 months), and greater number of patients free from progression at 1 year (14% versus 8%) compared with paclitaxel plus topotecan. There was no difference in overall survival. Toxicities were similar in the two treatment arms. Conclusions. The paclitaxel–carboplatin–etoposide combination produced a superior overall response rate and time to progression in patients with extensive-stage small cell lung cancer compared with paclitaxel plus topotecan. The platinum compounds continue to be a necessary component of the initial therapy for these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text